BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a global healthcare and specialty pharmacy solutions company, is pleased to be recognized as part of The Financial Times’ list of “Americas’ Fastest Growing Companies 2022,” a prestigious award presented by The Financial Times and Statista Inc., the world-leading statistics portal and industry ranking provider. This award goes to enterprises that contribute most heavily to economic growth. AscellaHealth ranked 162 with an Absolute Growth Rate of 417% and Compound Annual Growth Rate of 72.9%.
“We are thrilled to be ranked among this list of high-growth companies,” says Dea Belazi, president and CEO, AscellaHealth. “Our 1,556% four-year revenue increase validates our innovative patient-first approach for optimizing compliance to therapy, health outcomes and quality of life for patients with complex, chronic conditions or rare diseases. Our clinical programs help to ensure that specialty drugs are seamlessly accessed by prescribed patients.”
Out of the millions of active companies in North and South America, only 500 firms were awarded in the list. Criteria for inclusion included revenue of at least $1.5 million generated in 2020, an independent entity and not a subsidiary or branch office, and revenue growth between 2017 and 2020 that was primarily organic and not internally stimulated.
Belazi adds, “With health taking center stage over the past couple of years, it is no surprise that many of the fastest-growing companies on this list are medical technology solutions. Our success is built upon proprietary technology processes for innovative programs, as well as our comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services.”
About AscellaHealth LLC
AscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization serving patients, payers, life sciences and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. An Inc. 5000 2021 winner, AscellaHealth’s unique, patient-centric approach supports its strategic partnership with Optime Care and is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit www.AscellaHealth.com.
